Scandion Oncology Valuation
| SCOL Stock | SEK 0.07 0 1.43% |
Scandion Oncology seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Scandion Oncology from inspecting the company fundamentals such as Return On Equity of -0.74, price to sales of 969.63 X, and Current Valuation of (6.85 M) as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Scandion Oncology's price fluctuation is out of control at this time. Calculation of the real value of Scandion Oncology is based on 3 months time horizon. Increasing Scandion Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Scandion Oncology's intrinsic value may or may not be the same as its current market price of 0.07, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.071 | Real 0.0682 | Hype 0.07 | Naive 0.0781 |
The intrinsic value of Scandion Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Scandion Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Scandion Oncology AS helps investors to forecast how Scandion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Scandion Oncology more accurately as focusing exclusively on Scandion Oncology's fundamentals will not take into account other important factors: Scandion Oncology Total Value Analysis
Scandion Oncology AS is at this time anticipated to have takeover price of (6.85 M) with market capitalization of 111.79 M, debt of 0, and cash on hands of 131.54 M. The negative valuation of Scandion Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Scandion Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(6.85 M) | 111.79 M | 0 | 131.54 M |
Scandion Oncology Asset Utilization
One of the ways to look at asset utilization of Scandion is to check how much profit was generated for every dollar of assets it reports. Scandion Oncology has a negative utilization of assets of -0.42 %, losing kr0.004236 for each kronor of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each kronor of assets it has. In other words, asset utilization of Scandion Oncology AS shows how discouraging it operates for each kronor spent on its assets.Scandion Oncology Ownership Allocation
Scandion Oncology shows a total of 40.71 Million outstanding shares. About 98.18 % of Scandion Oncology outstanding shares are held by general public with 1.82 (%) owned by insiders and only 0.0 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Scandion Oncology Profitability Analysis
Net Loss for the year was (51.7 M) with loss before overhead, payroll, taxes, and interest of (32.32 M).About Scandion Oncology Valuation
The stock valuation mechanism determines Scandion Oncology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Scandion Oncology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Scandion Oncology. We calculate exposure to Scandion Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Scandion Oncology's related companies.Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.
8 Steps to conduct Scandion Oncology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Scandion Oncology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Scandion Oncology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Scandion Oncology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Scandion Oncology's revenue streams: Identify Scandion Oncology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Scandion Oncology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Scandion Oncology's growth potential: Evaluate Scandion Oncology's management, business model, and growth potential.
- Determine Scandion Oncology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Scandion Oncology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.